Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Blood (2023) 142 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2023-192042

Published: 2023

Journal Articles

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4296.

https://doi.org/10.1182/blood-2023-187044

Published: 2023

Journal Articles

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2023-181886

Published: 2023

Journal Articles

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 222.

https://doi.org/10.1182/blood-2023-179454

Published: 2023

Journal Articles

Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant

Andrius Zucenka, Ghayas C. Issa, Martha Arellano, Sajad Khazal, Nandita Khera, Wendy Stock, Branko Cuglievan, Yu Gu, Huy Van Nguyen, Angela R. Smith, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 4950.

https://doi.org/10.1182/blood-2023-189036

Published: 2023

Journal Articles

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Blood (2023) 142 (Supplement 1): 5933.

https://doi.org/10.1182/blood-2023-179609

Published: 2023

Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Blood (2023) 142 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2023-173162

Published: 2023

Journal Articles

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Naval Daver, Kyoo Hyung Lee, Yunsuk Choi, Brian A. Jonas, Martha Arellano, Paul B. Koller, Chul W. Jung, Sang Kyun Sohn, Amir T. Fathi, Jeong-Ok Lee, Sung-Soo Yoon, Justin M. Watts, Pankit Vachhani, Ho-Jin Shin, Jia Hu, Ranjeet Sinha, Nawazish Khan, William G. Rice, Rafael Bejar

Blood (2023) 142 (Supplement 1): 162.

https://doi.org/10.1182/blood-2023-182296

Published: 2023

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2023-189762

Published: 2023

Journal Articles

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Courtney D. DiNardo, Keith Pratz, Vinod Pullarkat, Brian A. Jonas, Martha Arellano, Pamela S. Becker, Olga Frankfurt, Marina Konopleva, Andrew H. Wei, Hagop M. Kantarjian, Tu Xu, Wan-Jen Hong, Brenda Chyla, Jalaja Potluri, Daniel A. Pollyea, Anthony Letai

Blood (2019) 133 (1): 7–17.

https://doi.org/10.1182/blood-2018-08-868752

Published: 2019

Includes: Supplemental data

Journal Articles

Outcomes after Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Phase Chronic Myeloid Leukemia

Jee Hyun Kong, Elliott F. Winton, MD, Leonard Heffner, MD, Manila Gaddh, MD, Brittany Hill, PA-C, MMSc, MSc, MPH, Martha Arellano, MD, Fuad El-Rassi, Audrey Kim, Anand Jillella, MD, Vamsi K Kota

Blood (2017) 130 (Supplement 1): 1607.

https://doi.org/10.1182/blood.V130.Suppl_1.1607.1607

Published: 2017

Journal Articles

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 2793.

https://doi.org/10.1182/blood.V128.22.2793.2793

Published: 2016

Journal Articles

Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions

Jee Hyun Kong, MD, Hanna Jean Khoury, MD, Elliott F. Winton, MD, Leonard T. Heffner, MD, Manila Gaddh, MD, Martha Arellano, MD, Fuad El-Rassi, MD, Audrey S Kim, RN, Anand Jillella, MD, Imre Bodó, MDPhD, Vamsi Kota, MD

Blood (2016) 128 (22): 3093.

https://doi.org/10.1182/blood.V128.22.3093.3093

Published: 2016

Journal Articles

A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 1622.

https://doi.org/10.1182/blood.V128.22.1622.1622

Published: 2016

Journal Articles

A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit

Guillermo Garcia Manero, Ehab Atallah, MD, Samer K Khaled, MD, Martha Arellano, MD, Mrinal M Patnaik, MBBS, Olatoyosi Odenike, MD, Hamid Sayar, MD, Mohan Tummala, Prapti A. Patel, MD, Richard G. Ghalie, MD, Bruno C. Medeiros, MD

Blood (2016) 128 (22): 100.

https://doi.org/10.1182/blood.V128.22.100.100

Published: 2016

Journal Articles

Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi-Institutional Review

Uma Borate, MD, Amanda Redden Hathaway, MD, Deniz Peker, MD, Bradford E Jackson, PhD, Vamsi K Kota, MD, Bijal D Shah, Ling Zhang, MD, Anand Jillella, MD, Martha Arellano, MD, Leonard T. Heffner, MD, Harry P Erba, MD PhD

Blood (2015) 126 (23): 4869.

https://doi.org/10.1182/blood.V126.23.4869.4869

Published: 2015

Journal Articles

Survival of Patients Diagnosed with Primary Refractory and Relapsed Acute Myeloid Leukemia from 2008-2012: A Single Institution Experience

Simon B. Zeichner, D.O., Shannon Gleason, M.L.S., Ana G. Antun, MD, Amelia Langston, MD, Leonard T Heffner, Jr., MD, Vamsi K Kota, MD, Manila Gaddh, MD, Martha Arellano, MD

Blood (2015) 126 (23): 4955.

https://doi.org/10.1182/blood.V126.23.4955.4955

Published: 2015

Journal Articles

ATRA Availability on Formulary for the Treatment of APL Across Hospitals in the State of Georgia

Sarah Wheeler, PharmD, Harika Puttagunta, MD, Minal Surati, PharmD, Elyse Panjic, PharmD, Arpita Shah, PharmD, Martha Arellano, MD, Anand Jillella, MD, Vamsi K Kota, MD

Blood (2015) 126 (23): 4924.

https://doi.org/10.1182/blood.V126.23.4924.4924

Published: 2015

Journal Articles

Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma

Vamsi K Kota, MD, Amanda Redden Hathaway, MD, Bijal D. Shah, MD, Deniz Peker, MD, Ling Zhang, MD, David L. Jaye, MD, Martha Arellano, MD, H Jean Khoury, Anand P Jillella, MD, Elliott F. Winton, MD, Leonard T Heffner, Jr., MD, Uma Borate, MD

Blood (2015) 126 (23): 3762.

https://doi.org/10.1182/blood.V126.23.3762.3762

Published: 2015

Journal Articles

Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA

Anand Jillella, MD, Martha Arellano, MD, Asad Bashey, MD PhD, Sarah I. Vidito, DO, Robert K. Stuart, MD, Caleb Leung, Kaitlin Sitchenko, Manila Gaddh, MD, Leonard T Heffner, Jr., MD, Ravindra B. Kolhe, MD PhD, Jacques Galipeau, MD, Amelia Langston, MD, Vamsi K Kota, MD

Blood (2015) 126 (23): 3779.

https://doi.org/10.1182/blood.V126.23.3779.3779

Published: 2015

NARROW

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Outcomes after Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Phase Chronic Myeloid Leukemia

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions

A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States

A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit

Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi-Institutional Review

Survival of Patients Diagnosed with Primary Refractory and Relapsed Acute Myeloid Leukemia from 2008-2012: A Single Institution Experience

ATRA Availability on Formulary for the Treatment of APL Across Hospitals in the State of Georgia

Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma

Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only